SEOUL, Jan. 13 (Korea Bizwire) — Samsung Biologics, a major South Korean contract drug manufacturer, said Thursday it plans to start building a fifth plant this year to meet rising orders. The company’s fourth plant, currently under construction, is set to be partially operational from October starting with a bioreactor capacity of 60,000 liters, CEO [...]
SEOUL, Dec. 14 (Korea Bizwire) — British-Swedish pharmaceutical giant AstraZeneca said Tuesday that Samsung Biologics Co., the biotech arm of Samsung Group, will manufacture its antibody combination against COVID-19. Under an agreement valued at approximately US$380 million, Samsung Biologics will manufacture AZD7442 — AstraZeneca’s combination of two long-acting antibodies in development for the potential treatment [...]
SEOUL, Nov. 25 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. said Thursday it has signed a supply agreement with U.S.-based biotech company GreenLight Biosciences. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will manufacture drug substances for GreenLight’s mRNA COVID-19 vaccine candidate. Samsung Biologics will manufacture drug substances of the mRNA [...]
SEOUL, Oct. 28 (Korea Bizwire) – Samsung Biologics Co., a major South Korean contract drugs manufacturer, on Thursday began to supply the first batch of Moderna vaccines manufactured in South Korea. In May, the biotech unit of South Korea’s largest conglomerate Samsung Group, signed a contract with Moderna Inc. to provide contract manufacturing organization services [...]
SEOUL, Oct. 26 (Korea Bizwire) — The first batch of 2.43 million doses of Moderna vaccines manufactured by South Korean biopharmaceutical firm Samsung Biologics Co. will be provided here this week, health authorities said Tuesday. In May, the biotech unit of Samsung Group signed a contract with the U.S. drugmaker to provide contract manufacturing organization [...]
SEOUL, May 23 (Korea Bizwire) – South Korea, touted as one of most successful countries in containing the new coronavirus pandemic without lockdowns, is gearing up for its next step to emerge as a global vaccine hub, with four COVID-19 vaccines already being or set to be produced here. The country’s vision to become a [...]
WASHINGTON/SEOUL, May 22 (Korea Bizwire) — Samsung Biologics, a South Korean biopharmaceutical firm, signed a deal Saturday to manufacture Moderna’s COVID-19 vaccine at its local factory. Under the agreement, the biotech unit of Samsung Group will provide the U.S. drugmaker with contract manufacturing organization (CMO) services for its mRNA vaccine. It means that some of [...]
SEOUL, April 28 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, said Tuesday its net income skyrocketed 66.4 percent on-year in the first quarter on the back of increased sales. The company’s net profit reached 61 billion won (US$54.8 million) during the Jan.-April period, compared with a net [...]
SONGDO, March 19 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. will accelerate its new drug development to secure future growth engines, its chief said Friday. Samsung Biologics is a leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of biopharmaceutical products for major pharmaceutical firms from both home [...]
SEOUL, Jan. 26 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, said Tuesday its net income increased 18.8 percent on-year in 2020 on the back of improved factory utilization and increased sales. The company’s net profit reached 241 billion won (US$217.8 million) in 2020, compared with a net [...]